MarketCapExport financials
iBio (IBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
iBio Financial Ratios 2026-2010 | IBIO
Brief overview of iBio's financial ratios
The review covers five available annual periods spanning 2019 to 2025.
The valuation comparison uses P/S 151.45x (median 33.54x), P/B 4.07x (median 0.35x). The combined multiple level is about 700.9% above the company's historical norm, leaving less valuation cushion.
Current measures of operating quality are ROE -123.5%, ROA -79.3%, ROCE -125%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
PEG is 0.51x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
Valuation takeaway
iBio's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.3 | -3.3 | -0.3 | -0.0 | -0.4 | - | -17.9 | -0.7 | -0.5 | -1.9 | -5.1 | -7.0 | -6.7 | -4.0 | -8.2 | -6.9 | - |
P/S |
1415.2 | 151.4 | 33.5 | - | 11.8 | - | 179.4 | 6.5 | 19.6 | 70.1 | 53.0 | 25.1 | 119.8 | 24.5 | 36.5 | 160.2 | - |
EPS |
-0.3 | -1.8 | -6.5 | -106.2 | -5.8 | -3 | -0.6 | -0.9 | -1.5 | -1.6 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.4 | - |
EV (Enterprise Value) |
98.5 M | 60.3 M | 747 K | 21.7 M | 35.4 M | -39 M | 276 M | 36.8 M | 31.2 M | 46.6 M | 69.7 M | 38.2 M | 21.4 M | 24.6 M | 44.6 M | 87.6 M | -910 K |
EBITDA per Share |
-0.33 | -1.73 | -4.18 | -46.8 | -3.14 | -3.92 | -0.187 | -0.742 | -1.18 | -1.41 | -1.11 | -0.882 | -0.553 | -1.28 | -2.28 | -3 | - |
EV/EBITDA |
-2.8 | -3.3 | -0.0 | -0.8 | -1.3 | 1.3 | -20.4 | -0.6 | 0.6 | -1.6 | -3.0 | -5.9 | -6.0 | -3.2 | -4.6 | -8.7 | - |
PEG |
-0.02 | -0.01 | -0.0 | -0.0 | -0.0 | - | 0.51 | 0.02 | 0.14 | -0.06 | -0.15 | -0.14 | 0.12 | 0.56 | 0.13 | -0.09 | - |
P/B |
1.7 | 4.1 | 0.4 | 0.0 | 0.3 | - | 5.2 | 5.3 | 0.5 | 3.1 | 2.1 | 4.1 | 4.0 | 4.9 | 7.6 | 423.6 | - |
P/CF |
-6.1 | -4.0 | -0.4 | -0.0 | -0.6 | - | -20.3 | -0.9 | -0.6 | -1.9 | -6.2 | -9.4 | -5.6 | -4.9 | -7.5 | -15.3 | - |
ROE % |
-38.55 | -123.50 | -116.80 | -422.66 | -79.24 | -21.37 | -29.04 | -716.04 | -99.63 | -163.01 | -40.61 | -58.99 | -60.11 | -122.30 | -92.01 | -6174.90 | - |
ROA % |
-33.34 | -79.26 | -86.68 | -157.76 | -50.60 | -15.79 | -17.45 | -57.52 | -37.38 | -40.36 | -18.92 | -53.03 | -56.45 | -66.26 | -58.13 | -165.52 | - |
ROCE % |
-41.00 | -125.01 | -78.01 | -190.77 | -46.78 | -28.65 | -15.74 | -58.20 | -34.66 | -41.99 | -20.06 | -59.35 | -62.96 | -131.55 | -151.19 | -4909.43 | - |
Current Ratio |
7.4 | 2.8 | 3.9 | 1.6 | 2.8 | 3.8 | 11.8 | 1.4 | 8.0 | 4.3 | 10.4 | 8.0 | 9.9 | 1.5 | 1.9 | 0.6 | - |
DSO |
- | - | - | - | 138.1 | 38.6 | 1253.2 | 17.5 | 61.7 | 162.1 | 233.3 | 87.7 | 365.0 | 365.0 | 100.4 | 241.5 | - |
DIO |
- | - | - | - | 3318.0 | 3.4 | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | 5507.1 | 500.9 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | 3456.1 | 41.9 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | -2051.0 | -459.0 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios iBio
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.06 | -0.09 | -0.11 | -0.09 | -0.11 | - | -0.49 | -0.48 | -0.46 | - | -0.85 | -4.42 | -4.8 | - | -11.07 | -68.43 | -2.05 | -5.54 | -1.42 | -1.37 | -1.03 | -2.4 | -0.04 | -0.04 | -0.05 | -0.04 | -0.05 | -0.69 | -0.21 | -0.69 | -0.21 | -0.24 | -0.25 | -0.24 | -0.25 | -0.41 | -0.42 | -0.04 | -0.04 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | 0.01 | -0.03 | 0.01 | -0.02 | -0.04 | -0.02 | -0.04 | -0.05 | 0.01 | -0.05 | 0.01 |
EBITDA per Share |
- | -0.07 | -0.09 | -0.11 | -0.1 | -0.11 | - | -0.49 | -0.48 | -0.46 | - | -0.98 | -2.42 | -4.12 | - | -9.35 | -21.5 | -0.83 | -2.04 | -0.76 | -0.82 | -0.56 | -1.33 | -0.03 | -0.04 | -0.04 | -39.5 | -42 | -83.5 | -173 | -81.8 | -173 | -205 | -211 | -0.21 | -0.2 | -0.32 | -0.33 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | - | -0.03 | - | -0.03 | -0.04 | -0.03 | -0.04 | -0.08 | -0.07 | -0.08 | -0.07 |
ROE % |
-36.08 | -51.98 | -52.21 | -79.03 | -100.23 | -106.79 | -96.59 | -109.34 | -155.91 | -168.01 | -145.54 | -187.48 | -352.98 | -301.19 | -257.68 | -339.09 | -312.76 | -147.66 | -119.07 | -56.87 | -48.32 | -42.74 | -43.25 | -38.40 | -44.65 | 699.13 | 939.43 | 801.04 | 633.15 | -143.38 | -408.02 | -282.92 | -128.93 | -138.51 | -165.56 | -181.65 | -197.37 | -225.21 | -207.28 | -196.03 | -183.91 | -134.67 | -110.21 | -97.71 | -82.98 | -71.75 | -79.27 | -86.38 | -93.42 | -96.58 | -63.98 | -68.94 | -38.35 | -46.73 | -98.27 | -83.57 | -124.30 | -618.49 | -530.38 | -1328.15 | -1100.05 | 43.24 | -815.13 | 194.84 |
ROA % |
-31.89 | -45.85 | -45.76 | -57.24 | -68.44 | -70.75 | -61.83 | -68.15 | -66.84 | -61.98 | -45.71 | -62.14 | -120.59 | -117.90 | -102.65 | -154.64 | -148.94 | -93.60 | -78.38 | -40.58 | -35.05 | -31.22 | -31.42 | -22.82 | -24.03 | -28.78 | -35.05 | -39.80 | -46.06 | -46.81 | -44.37 | -45.12 | -42.68 | -42.79 | -43.98 | -44.08 | -45.27 | -41.39 | -36.31 | -32.42 | -27.34 | -43.89 | -53.39 | -69.94 | -79.45 | -70.56 | -75.87 | -77.47 | -83.32 | -85.24 | -58.90 | -50.81 | -25.05 | -23.89 | -54.72 | -48.32 | -73.38 | -89.47 | -56.93 | -67.74 | -41.51 | 6.87 | -21.78 | 5.22 |
ROCE % |
-38.11 | -54.81 | -54.64 | -80.81 | -101.99 | -108.42 | -97.80 | -112.38 | -118.40 | -125.23 | -102.10 | -137.58 | -179.17 | -146.07 | -107.43 | -136.12 | -109.19 | -61.00 | -50.41 | -33.20 | -31.29 | -30.33 | -33.79 | -35.64 | -41.23 | 583.21 | 791.29 | 676.52 | 532.24 | -121.41 | -351.15 | -247.89 | -115.81 | -123.45 | -146.55 | -160.16 | -173.43 | -209.62 | -200.38 | -195.40 | -189.43 | -137.98 | -112.30 | -98.90 | -83.31 | -72.11 | -79.66 | -86.91 | -93.98 | -97.14 | -66.88 | -71.84 | -43.89 | -68.92 | -112.74 | -107.94 | -142.02 | -971.64 | -1194.44 | -2531.06 | -3684.09 | -262.39 | -1364.10 | -1182.36 |
Current Ratio |
2.8 | 10.3 | 8.2 | 7.9 | 8.2 | 7.9 | 2.8 | 2.5 | 2.8 | 3.6 | 3.9 | 2.0 | 1.4 | 1.5 | 1.6 | 1.6 | 1.6 | 2.3 | 2.8 | 3.2 | 3.5 | 3.3 | 3.8 | 3.8 | 3.8 | 3.1 | 3.9 | 3.1 | 1.0 | 0.9 | 1.3 | 1.2 | 1.4 | 1.4 | 1.5 | 1.6 | 1.3 | 1.2 | 1.3 | 1.2 | 1.6 | 1.8 | 1.6 | 1.8 | 6.1 | 7.3 | 7.5 | 9.0 | 7.5 | 5.5 | 16.4 | 16.4 | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | 29.7 | - | 29.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.3 | 86.4 | 343.8 | 462.8 | 36.1 | 31.1 | 41.7 | 9.7 | 33.3 | 43.5 | 72.7 | 28.2 | 106.5 | 19.2 | 196.7 | 10.5 | 123.4 | 118.1 | 162.7 | 58.1 | 246.6 | 118.6 | 221.0 | 588.9 | 231.8 | 232.2 | 263.8 | 303.0 | 293.4 | 72.6 | 11.4 | 51.0 | 67.5 | - | - | - | - | - | 86.7 | 82.1 | 68.4 | 108.1 | 94.6 | 134.3 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5008.3 | 1038.9 | 700.3 | 16.1 | 2.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7621.3 | 2031.3 | 5185.3 | 1344.3 | 431.5 | 867.3 | 1433.1 | - | 1167.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5036.6 | 1125.2 | 1044.2 | 478.9 | 38.6 | 31.1 | 41.7 | 9.7 | 33.3 | 43.5 | 72.7 | 28.2 | 106.5 | 19.2 | 196.7 | 10.5 | 123.4 | 118.1 | 162.7 | 58.1 | 246.6 | 118.6 | 221.0 | 588.9 | 231.8 | 232.2 | 263.8 | 303.0 | 293.4 | 72.6 | 11.4 | 51.0 | 67.5 | - | - | - | - | - | 86.7 | 82.1 | 68.4 | 108.1 | 94.6 | 134.3 | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2584.7 | -906.1 | -4141.1 | -865.4 | -392.9 | -836.2 | -1391.4 | 9.7 | -1134.4 | 43.5 | 72.7 | 28.2 | 106.5 | 19.2 | 196.7 | 10.5 | 123.4 | 118.1 | 162.7 | 58.1 | 246.6 | 118.6 | 221.0 | 588.9 | 231.8 | 232.2 | 263.8 | 303.0 | 293.4 | 72.6 | 11.4 | 51.0 | 67.5 | - | - | - | - | - | 86.7 | 82.1 | 68.4 | 108.1 | 94.6 | 134.3 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company iBio, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
Russia
Schweiz
Britain
